MedTrace Logo

Study of Danggui Buxue Decoction in Preventing Neutropenia

NCT02005783 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2015-12-30

No results posted yet for this study

Summary

To evaluate EC/TC (epirubicin and cyclophosphomide or docetaxel and cyclophosphomide) with EC/TC plus DBD (Danggui Buxue Decoction) in adjuvant treatment of breast cancer patients. The aim is to evaluate whether DBD can decrease the incidence of grade 3/4 neutropenia induced by EC/TC regimen during chemotherapy.

Conditions

Interventions

DRUG

DBD

DBD:one dose of medicine twice per day, orally

DRUG

Epirubicin

Epirubicin:90mg/m2, d1, q3w\*4

DRUG

Cyclophosphamide

Cyclophosphamide:600mg/m2, d1, q3w\*4

DRUG

Docetaxel

Docetaxel:75mg/m2, d1, q3w\*4

Sponsors & Collaborators

  • Shanghai Jiao Tong University School of Medicine

    lead OTHER

Principal Investigators

  • Kunwei Shen, Dr · Ruijin Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2015-08-31
Completion
2015-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02005783 on ClinicalTrials.gov